Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths | 0.20 [0.02, 1.72] | | < 1 | | 0% | 1 study (1/-) | 92.8 % | NA | not evaluable | | crucial | - |
symptomatic Covid-19 | 0.33 [0.26, 0.43] | | < 1 | | 0% | 1 study (2/-) | 100.0 % | NA | not evaluable | | important | - |
asymptomatic COVID case | 0.33 [0.23, 0.48] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
infection (PCR positive symptomatic or not) | 0.44 [0.33, 0.59] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
severe COVID-19 occurrence | 0.49 [0.02, 14.54] | | < 1 | | 0% | 1 study (1/-) | 65.9 % | NA | not evaluable | | non important | - |
transmission (symptomatic confirmed COVID19) | 0.52 [0.46, 0.60] | | < 1 | | 0% | 2 studies (-/2) | 100.0 % | serious | not evaluable | low | non important | - |
vaccine efficacy after dose 1 (and before dose 2) | 0.24 [0.14, 0.41] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
serious adverse events | 0.86 [0.64, 1.17] | | < 1 | | 0% | 1 study (1/-) | 82.5 % | NA | not evaluable | | important | - |
adverse events | 1.62 [1.54, 1.70] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | NA | not evaluable | | non important | - |
ATE (Myocardial infarction or ischemic stroke) | 0.39 [0.14, 1.06] | | < 1 | | 0% | 2 studies (2/-) | 96.8 % | NA | not evaluable | | non important | - |
ATE with thrombocytopenia | 1.57 [0.65, 3.79] | | < 1 | | 0% | 1 study (-/1) | 15.8 % | NA | not evaluable | | non important | - |
deep vein thrombosis | 1.11 [0.85, 1.44] | | < 1 | | 54% | 3 studies (-/3) | 21.5 % | critical | not evaluable | very low | non important | - |
Guillain-Barré syndrome | 1.00 [0.03, 29.81] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
immune thrombocytopenia | 1.49 [0.84, 2.63] | | < 1 | | 75% | 3 studies (-/3) | 8.5 % | serious | not evaluable | low | non important | - |
intracranial hemorrhage | 0.32 [0.04, 2.56] | | < 1 | | 0% | 3 studies (3/-) | 85.6 % | NA | not evaluable | | non important | - |
ischemic stroke | 0.25 [0.05, 1.30] | | < 1 | | 0% | 3 studies (3/-) | 95.0 % | NA | not evaluable | | non important | - |
Myocardial infarction | 0.26 [0.05, 1.37] | | < 1 | | 0% | 3 studies (3/-) | 94.3 % | NA | not evaluable | | non important | - |
pulmonary embolism | 0.44 [0.05, 3.75] | | < 1 | | 0% | 3 studies (3/-) | 77.3 % | NA | not evaluable | | non important | - |
serious adverse events (SAE), any | 0.87 [0.71, 1.06] | | < 1 | | 0% | 3 studies (3/-) | 91.6 % | NA | not evaluable | | non important | - |
splanchnic vein thrombosis (SVT) | 1.38 [0.72, 2.65] | | < 1 | | 0% | 1 study (-/1) | 16.7 % | NA | not evaluable | | non important | - |
stroke (non-specific, hemorrhagic, and ischemic) | 0.99 [0.88, 1.10] | | < 1 | | 12% | 2 studies (-/2) | 59.1 % | critical | not evaluable | very low | non important | - |
stroke with thrombocytopenia | 2.21 [0.99, 4.92] | | < 1 | | 0% | 1 study (-/1) | 2.6 % | NA | not evaluable | | non important | - |
thrombocytopenia | 1.32 [1.04, 1.68] | | < 1 | | 92% | 3 studies (-/3) | 1.3 % | critical | not evaluable | very low | non important | - |
venous thromboembolism | 0.24 [0.01, 5.40] | | < 1 | | 0% | 1 study (1/-) | 81.1 % | NA | not evaluable | | non important | - |
VTE with thrombocytopenia | 1.09 [0.52, 2.29] | | < 1 | | 0% | 1 study (-/1) | 41.0 % | NA | not evaluable | | non important | - |
AE of interest endpoints 00 |
cerebral venous sinus thrombosis (CVST) | 6.89 [0.82, 57.62] | | < 1 | | 92% | 2 studies (-/2) | 3.8 % | critical | not evaluable | very low | important | - |
Bell's palsy | 0.98 [0.20, 4.83] | | < 1 | | 0% | 1 study (2/-) | 51.2 % | NA | not evaluable | | non important | - |
immediate allergic reaction | 1.95 [0.07, 58.15] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
multiple sclerosis | 1.95 [0.07, 58.15] | | < 1 | | 0% | 1 study (1/-) | 35.2 % | NA | not evaluable | | non important | - |
myelitis | 1.95 [0.18, 21.52] | | < 1 | | 0% | 1 study (1/-) | 29.4 % | NA | not evaluable | | non important | - |
Potential Immune Gastrointestinal disorders | 0.33 [0.03, 3.13] | | < 1 | | 0% | 1 study (1/-) | 83.3 % | NA | not evaluable | | non important | - |
Potential Immune Musculoskeletal disorders | 0.98 [0.06, 15.60] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
Potential Immune Neuroinflammatory disorders | 1.22 [0.33, 4.54] | | < 1 | | 0% | 1 study (1/-) | 38.4 % | NA | not evaluable | | non important | - |
Potential Immune Skin disorders | 0.73 [0.16, 3.27] | | < 1 | | 0% | 1 study (1/-) | 65.8 % | NA | not evaluable | | non important | - |
Potential Immune Vasculitides | 0.49 [0.02, 14.54] | | < 1 | | 0% | 1 study (1/-) | 65.9 % | NA | not evaluable | | non important | - |
Thromboembolic events | 0.49 [0.15, 1.62] | | < 1 | | 0% | 1 study (1/-) | 87.9 % | NA | not evaluable | | non important | - |